PL2817299T3 - Podstawione związki chromanowe jako modulatory receptorów wapniowych - Google Patents

Podstawione związki chromanowe jako modulatory receptorów wapniowych

Info

Publication number
PL2817299T3
PL2817299T3 PL13712928T PL13712928T PL2817299T3 PL 2817299 T3 PL2817299 T3 PL 2817299T3 PL 13712928 T PL13712928 T PL 13712928T PL 13712928 T PL13712928 T PL 13712928T PL 2817299 T3 PL2817299 T3 PL 2817299T3
Authority
PL
Poland
Prior art keywords
receptor modulators
calcium receptor
chroman compounds
substituted chroman
substituted
Prior art date
Application number
PL13712928T
Other languages
English (en)
Inventor
Manojkumar Ramprasad Shukla
Ankush Gangaram Sarde
Rajeshkumar Maganlal Loriya
Vipul Dilip Pachpute
Navnath Bajirao Walke
Talha Hussain Khan
Sanjeev Anant Kulkarni
Venkata P. Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of PL2817299T3 publication Critical patent/PL2817299T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
PL13712928T 2012-02-24 2013-02-22 Podstawione związki chromanowe jako modulatory receptorów wapniowych PL2817299T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
EP13712928.4A EP2817299B1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
PL2817299T3 true PL2817299T3 (pl) 2019-12-31

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13712928T PL2817299T3 (pl) 2012-02-24 2013-02-22 Podstawione związki chromanowe jako modulatory receptorów wapniowych

Country Status (44)

Country Link
US (3) US9163001B2 (pl)
EP (1) EP2817299B1 (pl)
JP (1) JP6114316B2 (pl)
KR (1) KR102041154B1 (pl)
CN (1) CN104350047B (pl)
AP (1) AP2014007919A0 (pl)
AR (1) AR090135A1 (pl)
AU (1) AU2013223715B2 (pl)
BR (1) BR112014021133B1 (pl)
CA (1) CA2864332C (pl)
CL (1) CL2014002218A1 (pl)
CO (1) CO7160018A2 (pl)
CR (1) CR20140424A (pl)
CU (1) CU24325B1 (pl)
CY (1) CY1122017T1 (pl)
DK (1) DK2817299T3 (pl)
DO (1) DOP2014000193A (pl)
EA (1) EA026940B9 (pl)
ES (1) ES2743492T3 (pl)
GE (2) GEAP201813579A (pl)
GT (1) GT201400179A (pl)
HR (1) HRP20191606T1 (pl)
HU (1) HUE046172T2 (pl)
IL (1) IL234252A (pl)
IN (1) IN2014MN01672A (pl)
LT (1) LT2817299T (pl)
MA (1) MA35937B1 (pl)
MX (1) MX355670B (pl)
MY (1) MY171374A (pl)
NI (1) NI201400094A (pl)
NZ (1) NZ628627A (pl)
PE (1) PE20142281A1 (pl)
PH (1) PH12014501891B1 (pl)
PL (1) PL2817299T3 (pl)
PT (1) PT2817299T (pl)
RS (1) RS59172B1 (pl)
SG (1) SG11201405117SA (pl)
SI (1) SI2817299T1 (pl)
SM (1) SMT201900506T1 (pl)
TN (1) TN2014000352A1 (pl)
TW (1) TWI617549B (pl)
UA (1) UA112679C2 (pl)
WO (1) WO2013124828A1 (pl)
ZA (1) ZA201405990B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24325B1 (es) * 2012-02-24 2018-03-13 Lupin Atlantis Holdings Sa Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores
WO2014033604A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
EP3039014A1 (en) 2013-08-28 2016-07-06 Lupin Atlantis Holdings SA Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
WO2021100059A1 (en) * 2019-11-19 2021-05-27 Lupin Limited Process for preparing chroman compounds
CN114901273B (zh) * 2019-12-27 2024-08-27 鲁平有限公司 Casr调节剂的药物组合物及其方法和用途
PT4090654T (pt) * 2020-01-17 2025-10-07 Lupin Ltd Métodos, processos e intermediários para a preparação de compostos de cromano
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSRアンタゴニスト
WO2006123725A1 (ja) 2005-05-19 2006-11-23 Astellas Pharma Inc. ピロリジン誘導体またはその塩
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
EP2212284B1 (en) * 2007-10-15 2014-04-30 Amgen Inc. Calcium receptor modulating agents
CN101970394B (zh) 2007-11-23 2015-05-27 利奥制药有限公司 用于治疗疾病的新的环烃化合物
JP5685941B2 (ja) 2008-10-03 2015-03-18 味の素株式会社 CaSRアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
US9382216B2 (en) 2011-03-10 2016-07-05 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
AP2013007153A0 (en) 2011-03-18 2013-09-30 Lupin Ltd Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators
CU24325B1 (es) * 2012-02-24 2018-03-13 Lupin Atlantis Holdings Sa Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores

Also Published As

Publication number Publication date
CA2864332C (en) 2020-08-25
AR090135A1 (es) 2014-10-22
GEP20186911B (en) 2018-10-25
PH12014501891B1 (en) 2021-05-05
GEAP201813579A (en) 2018-06-25
PH12014501891A1 (en) 2015-02-09
CU20140103A7 (es) 2015-01-29
SI2817299T1 (sl) 2019-10-30
CL2014002218A1 (es) 2015-03-06
CO7160018A2 (es) 2015-01-15
ES2743492T3 (es) 2020-02-19
HUE046172T2 (hu) 2020-02-28
HK1205117A1 (en) 2015-12-11
EA201491582A1 (ru) 2014-12-30
NZ628627A (en) 2017-02-24
PT2817299T (pt) 2019-09-23
AU2013223715A1 (en) 2014-08-28
CU24325B1 (es) 2018-03-13
WO2013124828A1 (en) 2013-08-29
TWI617549B (zh) 2018-03-11
BR112014021133B1 (pt) 2022-06-28
CR20140424A (es) 2015-01-13
IL234252A (en) 2017-02-28
GT201400179A (es) 2016-03-01
DOP2014000193A (es) 2017-01-15
MX2014010139A (es) 2015-09-04
US20170209410A1 (en) 2017-07-27
AU2013223715B2 (en) 2017-09-14
US20150368222A1 (en) 2015-12-24
ZA201405990B (en) 2015-11-25
CN104350047B (zh) 2017-05-24
KR20140135731A (ko) 2014-11-26
US9598391B2 (en) 2017-03-21
JP6114316B2 (ja) 2017-04-12
HRP20191606T1 (hr) 2019-12-13
SG11201405117SA (en) 2014-09-26
DK2817299T3 (da) 2019-09-16
EA026940B9 (ru) 2017-11-30
LT2817299T (lt) 2019-09-25
IN2014MN01672A (pl) 2015-05-29
CA2864332A1 (en) 2013-08-29
EP2817299B1 (en) 2019-06-12
US9987249B2 (en) 2018-06-05
JP2015508097A (ja) 2015-03-16
NI201400094A (es) 2015-03-27
US20150038546A1 (en) 2015-02-05
RS59172B1 (sr) 2019-10-31
PE20142281A1 (es) 2015-01-16
CY1122017T1 (el) 2020-10-14
SMT201900506T1 (it) 2019-11-13
MX355670B (es) 2018-04-25
CN104350047A (zh) 2015-02-11
TN2014000352A1 (en) 2015-12-21
KR102041154B1 (ko) 2019-11-07
AP2014007919A0 (en) 2014-09-30
US9163001B2 (en) 2015-10-20
UA112679C2 (uk) 2016-10-10
EA026940B1 (ru) 2017-06-30
EP2817299A1 (en) 2014-12-31
TW201336831A (zh) 2013-09-16
MY171374A (en) 2019-10-10
MA35937B1 (fr) 2014-12-01
BR112014021133A2 (en) 2018-09-11

Similar Documents

Publication Publication Date Title
PL2817299T3 (pl) Podstawione związki chromanowe jako modulatory receptorów wapniowych
DK2829161T3 (da) Forbedret lysstyringssystem
CO7010838A2 (es) Compuestos de imidazopirrolidinona
CL2013001255S1 (es) Unidad de control
DE102011006411B8 (de) Bremssteuersystem
DK3848027T3 (da) Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
CO6852069A2 (es) Compuestos novedosos como moduladores de proteínas cinasas
EP2914901A4 (en) Lighting system
PT3068786T (pt) Compostos de pirazolopirimidina
EP2920482A4 (en) BRAKE
ME03081B (me) Modulatora receptora androgena patentni zahtevi
EP2825878A4 (en) BACK PRESSURE CONTROL
DK3385252T3 (da) Cannabinoidreceptormodulatorer
BR112014030671A2 (pt) conjunto de controle de freio de estacionamento.
DK2938615T3 (da) Imidazopyridazin-derivater som GABAA-receptormodulatorer
EP2813205A4 (en) CALCIUM PHOSPHATE DISPERSION COMPOSITION
FI20126194A7 (fi) Hissijärjestelmä
EP2803201A4 (en) IMPROVED RETURN SYSTEM
EP2850078A4 (en) BENZOPYRYLIUMVERBINDUNGEN
BR112014028559A2 (pt) montagem de freio de aeronave
HUE036238T2 (hu) Szelektív androgén receptor modulátorokként ható indolkarbonitril vegyületek
DE112013003377A5 (de) Hebelsystem
PL2897604T3 (pl) Kompozycje do ulepszenia funkcji mózgu
EP2854797A4 (en) chroman
CO7020920A2 (es) Derivado de fenilazol sustituido